Use of Western medicine: Reduced dose of Western medicine (short term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Service outcomes: Hospitalisation · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS may leads to lower adverse effects: Extrapyramidal symptoms ‐ specific ‐ akathisia… compared with STANDARD DOSE ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Quality of life: No clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes global state: Relapse ( compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes mental state: BPRS (not improved, reduced rate < 30%, short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia
Clozapine: low dose (150 mg/day to 300 mg/day) showed no clear difference in mental state: clinically important response in mental state BPRS… compared with standard dose (301 mg/day to 600 mg/day) (low certainty).
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review